Plain-English translation of NCT07289763 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called in people who have primary membranous nephropathy, a condition where the immune system damages the filtering units in the kidneys. Researchers want to learn whether this medication is safe and whether it can help reduce protein loss in the urine and slow kidney damage. The study will enroll about 75 patients across multiple medical centers.
Primary membranous nephropathy is a serious kidney disease with limited treatment options, and many patients continue to lose dangerous amounts of protein in their urine despite current therapies. This trial exists to see whether this new treatment could offer patients a better option to protect their kidney function.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication as injections and visit the study center multiple times so doctors can monitor your kidney function, check for side effects, and measure how well the treatment is working. The study will track information about how your body processes the medication and how it affects your kidney disease over time. You'll be randomly assigned to receive one of several different treatment approaches being tested.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China